Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx Biopharma, Inc. to Present at Biotech Showcase™ 2018

GlobeNewswire December 29, 2017

Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen® at Contract Manufacturer

GlobeNewswire December 20, 2017

Hemispherx Highlights Year-To-Date Progress, Outlines Key Objectives

GlobeNewswire December 19, 2017

Hemispherx Biopharma, Inc. to Present at the 10th Annual LD Micro Main Event

Accesswire December 4, 2017

Hemispherx Biopharma, Inc. Presentation Now Available for On-Demand Viewing

PR Newswire November 6, 2017

Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd

PR Newswire October 30, 2017

Hemispherx Biopharma, Inc. to Webcast, Live, at VirtualInvestorConferences.com November 2

PR Newswire October 30, 2017

Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017

GlobeNewswire August 15, 2017

Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated

GlobeNewswire August 14, 2017

Hemispherx Biopharma to Host Conference Call to Discuss Second Quarter Financial Results on Tuesday, August 15, 2017

GlobeNewswire August 11, 2017

Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

GlobeNewswire August 8, 2017

Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue Syndrome

GlobeNewswire August 4, 2017

Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer

GlobeNewswire July 10, 2017

Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology

GlobeNewswire May 31, 2017

Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities

GlobeNewswire May 31, 2017

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017

GlobeNewswire May 15, 2017

Worthy Start of the Year for Biotech Companies

PR Newswire January 20, 2017

Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients

GlobeNewswire January 11, 2017

Hemispherx BioPharma CEO Talks About Ampligen, Alferon's Potential

Benzinga.com  January 3, 2017

Hemispherx Biopharma to Present at the 9th Annual LD Micro Main Event

GlobeNewswire November 21, 2016